Enveric Biosciences (ENVB) announced a second notice of allowance from the USPTO for novel compounds within its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders. The allowed patent application, titled “Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives,” covers a series of methylone-inspired compounds, which are structurally differentiated benzodioxole derivatives engineered as non-hallucinogenic modulators of neurotransmitters relevant for neuropsychiatric disorders.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Psychedelic: Clearmind expands trial for Alcohol Use Disorder
- Enveric Biosciences announces results of EB-003 preclinical model
- Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
- Enveric announces data broadening clinical potential for lead candidate
- Psychedelic: Clearmind engages government, political affairs consulting firm